We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $444.41 in the latest trading session, marking a +2% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.75%. Meanwhile, the Dow gained 1.86%, and the Nasdaq, a tech-heavy index, added 2.54%.
Shares of the drugmaker witnessed a loss of 3.83% over the previous month, trailing the performance of the Medical sector with its gain of 3.73%, and the S&P 500's loss of 1.63%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. It is anticipated that the company will report an EPS of $4.79, marking a 5.97% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $3.22 billion, up 8.46% from the prior-year quarter.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $19.15 per share and revenue of $13.03 billion. These results would represent year-over-year changes of +4.08% and +8.57%, respectively.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 22.76. This expresses a premium compared to the average Forward P/E of 20.9 of its industry.
It is also worth noting that VRTX currently has a PEG ratio of 1.66. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.46 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX - Free Report) closed at $444.41 in the latest trading session, marking a +2% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.75%. Meanwhile, the Dow gained 1.86%, and the Nasdaq, a tech-heavy index, added 2.54%.
Shares of the drugmaker witnessed a loss of 3.83% over the previous month, trailing the performance of the Medical sector with its gain of 3.73%, and the S&P 500's loss of 1.63%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. It is anticipated that the company will report an EPS of $4.79, marking a 5.97% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $3.22 billion, up 8.46% from the prior-year quarter.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $19.15 per share and revenue of $13.03 billion. These results would represent year-over-year changes of +4.08% and +8.57%, respectively.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% higher. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 22.76. This expresses a premium compared to the average Forward P/E of 20.9 of its industry.
It is also worth noting that VRTX currently has a PEG ratio of 1.66. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.46 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.